This week’s announcement about a new multibillion-dollar investment in PCI Pharma Services is good news for contract development and manufacturing organizations.
The 154,000-square-foot Bedford site will offer flexible, capital-efficient space for clinical and commercial life sciences manufacturing, according to the company.
The CDMO will provide end-to-end cell line development and clinical manufacturing support at sites in Seattle, Washington and Chiba, Japan, for Okayama University.